Comparison 2.
IM OLANZAPINE vs OTHER IM ANTIPSYCHOTICS
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Global effect: Did not respond ‐ by 2 hours (>=40% change on PANSS‐EC) | 2 | 482 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.00 [0.73, 1.38] |
| 2 Behaviour: 1. Leaving the study ‐ by 24 hours | 1 | 257 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.87 [0.36, 2.06] |
| 3 Behaviour: 2. Requiring addtional IM injection ‐ by 24 hours | 2 | 482 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.99 [0.71, 1.38] |
| 4 Behaviour: 3. Requiring additional benzodiazepines | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 4.1 by 24 hours | 2 | 482 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.57, 1.60] |
| 4.2 by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.81 [0.62, 1.06] |
| 5 Adverse event: 1a. EPS ‐ akathisia ‐ by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.51 [0.32, 0.80] |
| 6 Adverse event: 1b. EPS ‐ requiring anticholinergic medication | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 6.1 by 24 hours | 2 | 482 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.20 [0.09, 0.44] |
| 6.2 by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.08 [0.02, 0.24] |
| 7 Adverse event: 1c. EPS ‐ dystonia | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 7.1 by 24 hours | 2 | 482 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.05 [0.01, 0.44] |
| 7.2 by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.09 [0.00, 1.55] |
| 8 Adverse event: 1d. EPS ‐ general extrapyramidal symptoms | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 8.1 extrapyramidal syndrome | 1 | 257 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.14 [0.02, 1.10] |
| 8.2 general extrapyramidial symptoms ‐ by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.12 [0.02, 0.94] |
| 8.3 parkinsonism ‐ by 5 days (oral period) | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.59 [0.41, 0.87] |
| 9 Adverse event: 2. Serious adverse event | 1 | 225 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.66 [0.03, 15.94] |
| 10 Adverse event: 3. Others ‐ by 5 days (oral period) | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 10.1 agitation | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.31, 1.63] |
| 10.2 anxiety | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.56 [0.27, 1.17] |
| 10.3 headache | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.32, 2.86] |
| 10.4 insomnia | 1 | 238 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.58 [0.29, 1.18] |